Thousands of women in England who have gone through the menopause could receive new jab through the NHS to cut any risk of bone breaks

Thousands of women in England who have gone through the menopause could receive new jab through the NHS to cut any risk of bone breaks By Kate Pickles Health Editor Published: 23:38, 7 August 2024 | Updated: 23:51, 7 August 2024 e-mail View comments Thousands of women in England who have gone through the menopause could benefit from a new drug that reduces the risk of bone fractures. Abaloparatide, sold as Eladynos and made by Theramex, has been given the green light for NHS use by the National Institute for Health and Care Excellence (Nice). A pre-filled pen is used for injections into the skin at home once a day, stimulating the cells that bolster bone growth.

Bone density starts to decline in the lead up to the menopause because of a decrease in the levels of the female sex hormone oestrogen. The drug has been recommended for patients with a high risk of fractures with regulator Nice estimating that it could benefit more than 14,000 women who have gone through the menopause. The drug Abaloparatide has been recommended for patients with a high risk of fractures (file image) Regulator Nice estimates Abaloparatide could benefit more than 14,000 women who are post-menopause Dr Louise Newson, founder of Newson Health clinics, said hormone replacement therapy (HRT) should 'still be the first line of treatment' for most women, as a new jab was approved for women that could reduce the risk of bone breaks after the menopause Professor Jonathan Benger, deputy chief executive of Nice.